Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
517
datasets available to search
ShareScore release 0.9.0
Dataset results
517 results for “Checkpoint inhibitors”
RNA datasets to derive predictors for immune checkpoint inhibitor therapy of non-small cell lung cancer
<p>Nanostring nCounter datasets and corresponding clinical data of tumor samples of patients with advanced NSCLC who received anti-PD-1 immuntherapy. Prospectively divided into a discovery and a validation cohort.</p> <p>Please cite the corresponding publication in Annals of Oncology (10.1093/annonc/mdz049)</p>
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations
<p>This study aims to investigate the accumulation of genomic instability and chromosome segregation errors after the acquisition of resistance to CDK4/6i in ER+ breast cancer and to test the efficacy of mitotic kinase inhibitors as a potential treatment for CDK4/6i-resistant breast cancer patients.</p> <p><strong>This repository contains whole-exome and shallow whole-genome sequencing from luminal breast cancer cell lines (T47D, LY2, MDA-MB-361, CAMA1, MCF7, KPL1, ZR751, HCC1428) both at the untreated or Parental state and post resistance to Palbociclib.</strong></p> <p>Palbociclib resistance was developed by continuous dose-escalation of palbociclib up to 0.5-1 μM until cell growth was observed in the presence of the drug (6-8 months for cell lines). During this time, parental cell lines and organoids were cultured in regular media to match the time spent in culture. Once resistance was established, Palbo-R cell lines were cultured in a regular growth medium without palbociclib. Cells were cultured without palbociclib for at least two weeks before evaluating resistance.</p>
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
ClinicalTrials.gov study NCT02654587. IPD Sharing: NO. Countries: 10. Publications: 1.
Pretreatment Neutrophil-to-Lymphocyte Ratio, Mutational Load, and Outcomes in Patients Treated with Immune Checkpoint Inhibitors
<p>This dataset has been used to analyze the association between pre-treatment neutrophil-to-lymphocyte ratio and tumour mutational burden with survival and response to treatment in immunotherapy-treated patients with cancer. The dataset contains clinical and genomic data for 2,037 patients with 18 cancer types.</p>
Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors
<p>R markdown files and source data to reproduce figures from the manuscript "Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors"</p>
Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors - Dataset
<p>Dataset used from the publication "Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab" published in </p> <p>Cell. 2017 Nov 2;171(4):934-949.e16.</p> <p> doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.</p>
Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
<p><span>Adverse events(AEs) related to hepatotoxicity have been reported in patients treated with immune checkpoint inhibitors (ICIs). As the number of adverse events increases, it is necessary to assess the differences in each immune checkpoint inhibitor regimen. The purpose of this study was to examine the relationship between ICIs and hepatotoxicity in a scientific and systematic manner. Data were obtained from the FDA Adverse Event Reporting System database (FAERS) and included data from the first quarter of 2014 to the fourth quarter of 2021. Disproportionality analysis assessed the association between drugs and adverse reactions based on the reporting odds ratio (ROR) and information components (IC). 9,806 liver adverse events were reported in the FAERS database. A strong signal was detected in older patients (≥65 years) associated with ICIs. Hepatic adverse events were most frequently reported with Nivolumab (36.17%). Abnormal liver function, hepatitis, and autoimmune hepatitis were most frequently reported, and hepatitis and immune-mediated hepatitis signals were generated in all regimens. In clinical use, patients should be alert to these adverse effects, especially in elderly patients, who may be aggravated by the use of ICI.</span></p>
The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature
<p><strong>The datasets include the results obtained upon a literature search on different databases: Web of science, Scopus and Pubmed.</strong></p> <p>The combination of mesh terms searched in the databases were “extracellular matrix molecules” or “extracellular matrix remodeling” and “immune checkpoint inhibitors” or “immunotherapy”.</p>
Personalizing Immune Checkpoint Inhibitor Therapy
ClinicalTrials.gov study NCT03409341. IPD Sharing: YES. Countries: 1. Publications: 6.
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemot
ClinicalTrials.gov study NCT03558139. IPD Sharing: NO. Countries: 1. Publications: 0.
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
ClinicalTrials.gov study NCT02903914. IPD Sharing: NO. Countries: 4. Publications: 2.
Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)
ClinicalTrials.gov study NCT03963518. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
ClinicalTrials.gov study NCT04338269. IPD Sharing: YES. Countries: 15. Publications: 2.
DPX-Survivac and Checkpoint Inhibitor in DLBCL
ClinicalTrials.gov study NCT03349450. IPD Sharing: YES. Countries: 1. Publications: 2.
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive
ClinicalTrials.gov study NCT02852655. IPD Sharing: NO. Countries: 1. Publications: 1.
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
ClinicalTrials.gov study NCT03388632. IPD Sharing: YES. Countries: 1. Publications: 4.
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
ClinicalTrials.gov study NCT05195645. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
ClinicalTrials.gov study NCT04214418. IPD Sharing: YES. Countries: 1. Publications: 0.
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
ClinicalTrials.gov study NCT03453164. IPD Sharing: NO. Countries: 1. Publications: 5.
Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.